



ASX Release

Eastland to present at the 2010 Interscience Conference, Boston USA

Eastland Medical Systems Ltd (ASX:EMS) is delighted to announce that Dr Stephen Rusilia from the Kigali University Teaching Hospital in Rwanda who was the lead investigator from Eastland's recent Clinical Trial held in Rwanda, has had his paper titled "*Sublingual Artemether in Severe Childhood Malaria*" selected for inclusion into the program of the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy 2010 conference.

The Conference is the world's premier meeting on infectious diseases and antimicrobial agents, organized by the American Society for Microbiology (ASM). The conference will take place in Boston, September 12 - 15 (icaac.org) and this year is its 50th Anniversary. One of the keynote opening presentations will be given by Nobel Prize laureate Professor Barry Marshall, AC from the University of Western Australia.

Dr Rusilia will join speakers for this year's conference which is expected to attract more than 10,000 participants, including physicians, clinical microbiologists, researchers, pharmacists, trainees and other healthcare professionals from around the world.

The presentation titled "*Sublingual Artemether in Severe Childhood Malaria*" will detail the results from Eastland's recently completed Phase IIa clinical trial of ArTiMist™, a patented sublingual delivery technology designed to administer the drug Artemether.

An invitation to present a paper at such an eminent conference is a great honour for Eastland and its clinical trial team. Only papers presenting new or novel information is considered for presentation at this conference. Eastland considers that being invited to present at this conference is further testimony to the importance of its unique solution for the treatment of severe malaria in children, one of the major health challenges in Africa and other tropical regions around the world.

Eastland recently successfully completed its Phase IIa trials in Rwanda comparing ArTiMist™ with the current treatment, intravenous quinine. The trials targeted children with severe malaria. The results showed that ArTiMist™ rapidly kills the malaria parasites and is safe and well tolerated in patients.

Planning is underway for the Phase III Confirmatory trials scheduled to commence in September 2010.

Highlights

- Positive results achieved from Phase I multi and single dose clinical studies for ArTiMist™ indicating the formulation was well tolerated and showed no adverse effects in any of the study subjects.
- ArTiMist™ Clinical Field Trial completed in February 2010 in Rwanda.



ASX Release

Highlights

Further information:

Dermot Patterson
CEO and Company Secretary
Eastland Medical Systems Ltd
t: +61 8 6142 5555
www.eastlandmedical.com.au

For personal use only